1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–28.
2. Flegal KM, Carroll MD, Ogden CL. Prevalence and trends in obesity among US adults 1999–2000. JAMA 2002; 288: 1723–7.
3. Forclaz A, Maillard M, Nussberger J. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003; 41: 31–6.
4. Старостина Е.Г, Древаль А.В. Бигуаниды в лечении сахарного диабета. Мед. практика; 2000: 44.
5. Cusi К, DeFronzo RA. Metformin: a review of its metabolic effect. Diabetes 1998; 6: 89–131.
6. Davidson M., Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 99–110.
7. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An Update. Ann Intern Med 2002; 137: 25–33.
8. Арутюнов Г.П. Сахарный диабет и атеросклероз. Какова оптимальная стратегия сдерживания атеросклеротического процесса? Сердце. 2004; 3, 1 (13): 36–40.
9. Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074–81.
10. Gregori F, Ambrosi F, Manfrini S et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Med 1999; 16 (12): 1016–24.
11. Lalau JD, Vermersch A, Hary L et al. Type 2 diabetes in elderly: an assessment of metformin. Int J Clin Pharmacol Ther Toxicol 1990; 28: 329–32.
12. Patane G, Piro S, Rabuazzo AM et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2001; 49 (5): 735–40.
13. Соболев А.В. Новый подход к оценке индивидуальной суточной вариабельности ритма сердца у пациента. Кардиология. 2003; 8: 16–21.
14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.
15. Dunstan DW, Zimmet PZ, Welborn ТD et al. The rising prevalence of diabetes and imparted glucose tolerance. The Australian diabetes, obesity and lifystyle study. Diabetes Care 2002; 25: 829–34.
16. Edelstein SL, Knowler WC, Bain RP et al. Predictor of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997; 46; 701–10.
17. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346: 393–403.
18. Salpeter SR, Greyber E, Pasternak GA. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003; 163 (21): 2594–602.
19. International Diabetes Federation (IDF). Global guideline for type 2 diabetes 2005.
20. Nieuwenhuis-Ruifrok AE, Kuchenbecker WKH, Hoek A et al. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update 2009; 15: 57–68.
21. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303.
22. Trolle B, Flyvbjerg A, Kesmodel U et al. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 2007; 22: 2967–73.
23. Petersen JS, DiBona GF. Acute Sympathoinhibitory Actions of Metformin in Spontaneously Hypertensive Rats. Hypertension 1996; 27: 619–25.

В.Б.Мычка, К.П.Иванов, Т.А.Шишова, В.П.Масенко

ФГУ Российский кардиологический научно-производственный комплекс Минздравсоцразвития РФ